Mirxes Holding Company Limited (HKG:2629)

Hong Kong · Delayed Price · Currency is HKD

12.41

-3.15 (-20.24%)

Mar 31, 2026, 4:08 PM HKT

-57.21% (1Y)

Market Cap	3.66B
Revenue (ttm)	166.32M +19.3%
Net Income	-598.38M
EPS	-4.38
Shares Out	295.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,818,600
Open	15.80
Previous Close	15.56
Day's Range	12.38 - 17.08
52-Week Range	12.28 - 77.30
Beta	n/a
Analysts	Strong Buy
Price Target	100.75 (+711.85%)
Earnings Date	Aug 25, 2026

About Mirxes Holding Company

Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 347

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2629

Full Company Profile

Financial Performance

In 2024, Mirxes Holding Company's revenue was $20.28 million, a decrease of -16.14% compared to the previous year's $24.19 million. Losses were -$92.33 million, 33.4% more than in 2023.

Financial numbers in USD Financial Statements